Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 8;13(2):e065194.
doi: 10.1136/bmjopen-2022-065194.

Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review protocol

Seda Yerlikaya  1 , Lydia Marie-Luise Holtgrewe  2   3 , Tobias Broger  2 , Chris Isaacs  4 , Payam Nahid  5 , Adithya Cattamanchi  5   6 , Claudia M Denkinger  2
Affiliations

Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review protocol

Seda Yerlikaya et al. BMJ Open. .

Abstract

Introduction: In 2014, the WHO published high-priority target product profiles (TPPs) for new tuberculosis (TB) diagnostics to align end-user needs with test targets and specifications; nevertheless, no TB test meets these targets to date. The COVID-19-driven momentum in the diagnostics world offers an opportunity to address the long-standing lack of innovation in the field of TB diagnostics. This scoping review aims to summarise point-of-care (POC) molecular and antigen tests for COVID-19 diagnosis that, when applied to TB, potentially meet WHO TPPs. This summary of currently available innovative diagnostic tools will guide the development of novel TB diagnostics toward the WHO-set targets.

Methods and analysis: We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension Scoping Reviews recommendations. MEDLINE (via PubMed), bioRxiv, MedRxiv and other publicly available in vitro diagnostic test databases were searched on 23 November 2022. POC antigen or molecular tests developed for SARS-CoV-2 detection that meet the eligibility criteria will be included in the review. Developer description, test description, operation characteristics, pricing information, performance and commercialisation status of diagnostic tests identified will be extracted using a predefined standardised data extraction form. Two reviewers will independently perform the screening and data extraction. A narrative synthesis of the final data will be provided.

Ethics and dissemination: No ethical approval is required because individual patient data will not be included. The findings will be published in open-access scientific journals.

Keywords: COVID-19; Diagnostic microbiology; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Global tuberculosis report 2021. 2021. Available: https://www.who.int/publications-detail-redirect/9789240037021
    1. Reid MJA, Arinaminpathy N, Bloom A, et al. Building a tuberculosis-free world: the lancet commission on tuberculosis. Lancet 2019;393:1331–84. 10.1016/S0140-6736(19)30024-8 - DOI - PubMed
    1. Vesga JF, Hallett TB, Reid MJA, et al. Assessing tuberculosis control priorities in high-burden settings: a modelling approach. Lancet Glob Health 2019;7:e585–95. 10.1016/S2214-109X(19)30037-3 - DOI - PubMed
    1. Chin DP, Hanson CL. Finding the missing tuberculosis patients. J Infect Dis 2017;216:S675–8. 10.1093/infdis/jix368 - DOI - PMC - PubMed
    1. Nathavitharana RR, Jijon DF, Pal P, et al. Diagnosing active tuberculosis in primary care. BMJ 2021;374:1590. 10.1136/bmj.n1590 - DOI - PubMed

Publication types